These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24204199)

  • 1. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
    Han S; Brenner JC; Sabolch A; Jackson W; Speers C; Wilder-Romans K; Knudsen KE; Lawrence TS; Chinnaiyan AM; Feng FY
    Neoplasia; 2013 Oct; 15(10):1207-17. PubMed ID: 24204199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
    Brenner JC; Ateeq B; Li Y; Yocum AK; Cao Q; Asangani IA; Patel S; Wang X; Liang H; Yu J; Palanisamy N; Siddiqui J; Yan W; Cao X; Mehra R; Sabolch A; Basrur V; Lonigro RJ; Yang J; Tomlins SA; Maher CA; Elenitoba-Johnson KS; Hussain M; Navone NM; Pienta KJ; Varambally S; Feng FY; Chinnaiyan AM
    Cancer Cell; 2011 May; 19(5):664-78. PubMed ID: 21575865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
    Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
    Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.
    Chatterjee P; Choudhary GS; Sharma A; Singh K; Heston WD; Ciezki J; Klein EA; Almasan A
    PLoS One; 2013; 8(4):e60408. PubMed ID: 23565244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W; Duan B; Zeng L
    Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.
    Chatterjee P; Choudhary GS; Alswillah T; Xiong X; Heston WD; Magi-Galluzzi C; Zhang J; Klein EA; Almasan A
    Mol Cancer Ther; 2015 Aug; 14(8):1896-906. PubMed ID: 26026052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
    Tian S; Lou L; Tian M; Lu G; Tian J; Chen X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):143. PubMed ID: 32711558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
    Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
    Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
    Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
    Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
    J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.
    Kötter A; Cornils K; Borgmann K; Dahm-Daphi J; Petersen C; Dikomey E; Mansour WY
    Mol Oncol; 2014 Dec; 8(8):1616-25. PubMed ID: 25028150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma.
    Camões MJ; Paulo P; Ribeiro FR; Barros-Silva JD; Almeida M; Costa VL; Cerveira N; Skotheim RI; Lothe RA; Henrique R; Jerónimo C; Teixeira MR
    PLoS One; 2012; 7(11):e49819. PubMed ID: 23185447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer.
    Li C; Zhang J; Wu Q; Kumar A; Pan G; Kelvin DJ
    Mol Cancer Ther; 2023 Mar; 22(3):306-316. PubMed ID: 36622760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
    Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
    Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective].
    Wiśnik E; Ryksa M; Koter-Michalak M
    Postepy Hig Med Dosw (Online); 2016 Apr; 70():280-94. PubMed ID: 27117104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.